Metabolic abnormalities in adult HIV infected population on antiretroviral medication in Malaysia: A cross-sectional survey

BMC Public Health

Volumn 13, Issue 1, 2013, Pages

  Hejazi, Nazisa ^a   Rajikan, Roslee ^a   Kwok Choong, Christopher Lee ^b   Sahar, Suzana ^a  

^a UNIVERSITI KEBANGSAAN MALAYSIA   (Malaysia)

^b HOSPITAL SUNGAI BULOH   (Malaysia)

Author keywords

ARV medication; Cardiovascular disease; Dyslipidemia; Fasting plasma glucose; HIV positive; Lipid disorders; Malaysia; Metabolic abnormalities; Protease inhibitor

Indexed keywords

CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; BLOOD; COMPLICATION; CROSS-SECTIONAL STUDY; DYSLIPIDEMIAS; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; HUMAN; MALAYSIA; MALE; MIDDLE AGED; PREVALENCE; RISK FACTOR; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHOLESTEROL; CROSS-SECTIONAL STUDIES; DYSLIPIDEMIAS; FEMALE; HIV INFECTIONS; HUMANS; MALAYSIA; MALE; MIDDLE AGED; PREVALENCE; RISK FACTORS; TRIGLYCERIDES; VIRAL LOAD;

EID: 84881443998     PISSN: None     EISSN: 14712458     Source Type: Journal    
DOI: 10.1186/1471-2458-13-758     Document Type: Review

References (68)

1. The Joint United Nations Programme on HIV/AIDS, Global report: UNAIDS report on the global AIDS epidemic 2012 http://www.unaids.org/en/media/unaids/ contentassets/documents/epidemiology/2012/gr2012/20121120-unaids-global-report- 2012-with-annexes-en.pdf. Accessed 10 November 2013.
2. Ministry of Health, Malaysia, Global AIDS Response 2012 Progress Report. Reporting Period: January 2010-december 2011 Putrajaya: Ministry of Health Malaysia 2012
3. World Bank, Countryclassification http://data.worldbank.org/country/ malaysia. Accessed 10 November 2012
4. World Health Organization, The Joint United Nations Programme on HIV/AIDS and The United Nations Children's Fund, Global HIV/AIDS response: epidemic update and health sector progress towards universal access: progress report 2011 Geneva: World Health Organization 2011
5. World Health Organization, Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach.-2010 rev Geneva: World Health Organization 2010 23819908
6. Prevalence of and risk factors for pre-diabetes in HIV-1-infected patients in Bangkok, Thailand. Srivanich N, Ngarmukos C, Sungkanuparph S, JIAPAC 2010 9 6 358 361 21075913
7. Diabetes mellitus, insulin resistance, and metabolic syndrome in HIV-positive patients in South India. Idiculla J, Ravindra'n GD, D'Souza J, Singh G, Furruqh S, Int J Gen Med 2011 4 73 21403795
8. Association of lopinavir concentrations and plasma lipid or glucose concentrations in HIV-infected South Africans. Sinxadi PZ, McIlleron HM, Dave JA, Smith PJ, Levitt NS, Maartens G, AIDS Res Ther 2012 9 1 32 10.1186/1742-6405-9-32 23098156
9. Metabolic syndrome among HIV-infected Taiwanese patients in the era of highly active antiretroviral therapy: prevalence and associated factors. Wu PY, Hung CC, Liu WC, Hsieh CY, Sun HY, Lu CL, Chien KL, J Antimicrob Chemother 2012 67 4 1001 1009 10.1093/jac/dkr558 22232517
10. Risk of diabetes in HIV infected veterans preand postHAART and the role of HCV coinfection. Butt AA, Fultz SL, Kwoh CK, Kelley D, Skanderson M, Justice AC, Hepatology 2004 40 1 115 119 10.1002/hep.20289 15239093
11. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using international diabetes foundation and adult treatment panel III criteria associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and hypoadiponectinemia. Samaras K, Wand H, Law M, Emery S, Cooper D, Carr A, Diabetes Care 2007 30 1 113 119 10.2337/dc06-1075 17192343
12. Incidence and risk factors for new-onset diabetes in HIV-infected patients the data collection on adverse events of anti-HIV drugs (D: A: D) study. De Wit S, Sabin CA, Weber R, Worm SW, Reiss P, Cazanave C, Phillips A, Diabetes Care 2008 31 6 1224 1229 10.2337/dc07-2013 18268071
13. Ten-year diabetes incidence in 1046 HIV-infected patients started on a combination antiretroviral treatment. Capeau J, Bouteloup V, Katlama C, Bastard JP, Guiyedi V, Salmon-Ceron D, Chêne G, AIDS 2012 26 3 303 10.1097/QAD.0b013e32834e8776 22089377
14. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study. Tsiodras S, Mantzoros C, Hammer S, Samore M, Arch Intern Med 2000 160 13 2050 10.1001/archinte.160.13.2050 10888979
15. Lipid profiles of Thai adult HIV-infected patients receiving protease inhibitors. Hiransuthikul N, Hiransuthikul P, Kanasook Y, Southeast Asian J Trop Med Public Health 2007 38 1 69 77 17539249
16. Prevalence of dyslipidemia and dysglycaemia in HIV infected patients. Manuthu EM, Joshi MD, Lule GN, Karari E, E AFR MED J 2008 85 1 10 17
17. Dyslipidaemia in HIV-1-infected patients receiving protease inhibitors after initial treatment with first-line-based non-nucleoside reverse transcriptase inhibitors: a cross-sectional study. Yone EWP, Kengne AP, Ashuntantang G, Betyoumin AF, Ngogang J, BMJ open 2012 2 4 1 5
18. Cardiovascular disease risk factors in HIV patients-association with antiretroviral therapy:Results from the DAD study. Friis-Moller N, Weber R, Reiss P, Thiébaut R, Kirk O, Monforte ADA, Lundgren JD, Aids 2003 17 8 1179 1193 10.1097/00002030-200305230-00010 12819520
19. Prevalence of dyslipidemia among HIV-infected patients using first-line highly active antiretroviral therapy in Southern Ethiopia: a cross-sectional comparative group study. Tadewos A, Addis Z, Ambachew H, Banerjee S, AIDS Res Ther 2012 9 1 31 10.1186/1742-6405-9-31 23095661
20. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? Fontas E, Van Leth F, Sabin CA, Friis-Møller N, Rickenbach M, DA Monforte A, Reiss P, J Infect Dis 2004 189 6 1056 1074 10.1086/381783 14999610
21. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Carr A, Samaras K, Chisholm DJ, Cooper DA, Lancet 1998 351 9119 1881 10.1016/S0140-6736(98)03391-1 9652687
22. HIV protease inhibitor-related lipodystrophy syndrome. Carr A, Clin Infect Dis 2000 30 Supplement 2 135 S142 10.1086/313854 10860898
23. Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. Currier JS, Lundgren JD, Carr A, Klein D, Sabin CA, Sax PE, Smieja M, Circulation 2008 118 2 29 e35 10.1161/CIRCULATIONAHA.107.189624 18566319
24. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Brown TT, Cole SR, Li X, Kingsley LA, Palella FJ, Riddler SA, Dobs AS, Arch Intern Med 2005 165 10 1179 10.1001/archinte.165.10.1179 15911733
25. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. Triant VA, Lee H, Hadigan C, Grinspoon SK, J Clin Endocrinol Metab 2007 92 7 2506 2512 10.1210/jc.2006-2190 17456578
26. Maraviroc can improve lipid profiles in dyslipidemic patients with HIV: results from the MERIT trial. MacInnes A, Lazzarin A, Di Perri G, Sierra-Madero JG, Aberg J, Heera J, Valdez H, HCT 2011 12 1 24 36
27. Combination antiretroviral therapy and the risk of myocardial infarction. Friis-Moller N, Sabin CA, Weber R, D'ArminioMonforte A, El-Sadr WM, Reiss P, Lundgren JD, New Engl J Med 2003 349 21 1993 2003 14627784
28. Metabolic syndrome in French HIV-infected patients: prevalence and predictive factors after 3 years of antiretroviral therapy. Biron A, Bobin-Dubigeon C, Volteau C, Piroth L, Perré P, Leport C, Biron C, AIDS Res Hum Retroviruses 2012 28 12 1672 1678 10.1089/aid.2012.0048 22731114
29. Buffalo hump seen in HIV-associated lipodystrophy is associated with hyperinsulinemia but not dyslipidemia. Mallon PW, Wand H, Law M, Miller J, Cooper DA, Carr A, JAIDS 2005 38 2 156 162 10.1097/01.qai.0000147527.64863.1a 15671800
30. The use of the Framingham equation to predict myocardial infarctions in HIVinfected patients: comparison with observed events in the D: A: D Study. Law MG, FriisMoller N, El-Sadr WM, Weber R, Reiss P, d'ArminioMonforte A, Lundgren JD, HIV Med 2006 7 4 218 230 10.1111/j.1468-1293.2006.00362.x 16630034
31. Differences in lipid measurements by antiretroviral regimen exposure in cohorts from Asia and Australia. Achhra AC, Amin J, Hoy J, Tanuma J, Sirisanthana T, Nolan D, Giles M, AIDS Res Ther 2012 2012 1 9
32. Prevalence of cardiovascular risk factors in Spanish HIV-infected patients on antiretroviral therapy.The CORONATOR Study [Abstract]. Estrada V, Bernardino JI, Casado JL, Domingo P, Masiá M, Iribarren JA, Santos J, Proceedings of the XIX International AIDS Conference 22-27 July 2012 Washingtone DC http://pag.aids2012.org/Abstracts.aspx?AID=15438
33. Dyslipidemia in an Asian population after treatment for two years with protease inhibitor-containing regimens. Kerr SJ, Duncombe C, Avihingsanon A, Ananworanich J, Boyd M, Sopa B, Ruxrungtham K, JIAPAC 2007 6 1 36 46 17329503
34. Metabolic effects associated to the highly active antiretroviral therapy (HAART) in AIDS patients. Domigos H, Cunha RVD, Paniago AMM, Martins DM, Elkhoury EB, Souza ASD, Braz J Infect Dis 2009 13 2 130 136 20140358
35. Dyslipidemia in an HIV-positive, antiretroviral treatment-naïve population in Dar es Salaam, Tanzania. Armstrong C, Liu E, Grinspoon S, Okuma J, Spiegelman D, Guerino C, Hawkins C, J Acquir Immune Defic Syndr 2011 57 2 141 10.1097/QAI.0b013e318219a3d1 21436713
36. The burden of metabolic diseases amongst HIV positive patients on HAART attending the Johannesburg Hospital. Julius H, Basu D, Ricci E, Wing J, KusariBasu J, Pocaterra D, Bonfanti P, Curr HIV Res 2012 9 4 247 252
37. Prevalence of HIV-associated metabolic abnormalities among patients taking first-line antiretroviral therapy in Uganda. Omech B, Sempa J, Castelnuovo B, Opio K, Otim M, Mayanja-Kizza H, Manabe YC, ISRN AIDS 2012 2012 1 6
38. Prevalence of lipodystrophy in Thai-HIV infected patients. Pharm SPMI, J Med Assoc Thai 2004 87 6 605 611 15279336
39. Body shape and metabolic abnormalities in Thai HIV-infected patients. Homsanit M, Nelson KE, Sonjai A, Anekthananon T, Suwanagool S, Cofrancesco J Jr, AIDS Res Hum Retroviruses 2007 23 11 1314 1321 10.1089/aid.2007.0013 18184072
40. Lipid profile changes in Thai HIV and tuberculosis co-infected patients receiving non-nucleoside reverse transcriptase inhibitors-based antiretroviral therapy. Journal of the Medical Association of Thailand. Mankhatitham W, Luaengniyomkul A, Manosuthi W, Chotmaihetthangphaet 2012 95 2 163
41. Lipodystrophy and dyslipidemia among patients taking first-line, World Health Organization-recommended highly active antiretroviral therapy regimens in Western India. Pujari SN, Dravid A, Naik E, Bhagat S, Tash K, Nadler JP, Sinnott JT, JAIDS 2005 39 2 199 202 15905737
42. Dyslipidemia among HIV-infected patients with tuberculosis taking once-daily nonnucleoside reverse-transcriptase inhibitor-based antiretroviral therapy in India. Padmapriyadarsini C, Kumar SR, Terrin N, Narendran G, Menon PA, Ramachandran G, Swaminathan S, Clin Infect Dis 2011 52 4 540 546 10.1093/cid/ciq195 21252141
43. Estimation of the concentration of LDL-cholesterol. Friedewald WT, Levy RI, Fredrickson DS, Clin Chem 1972 18 6 499 515 4337382
44. Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), Circulation 2001 106 3143 3421
45. Definition of metabolic syndrome: report of the national, heart, lung, and blood institute/american heart association conference on scientific issues related to definition. Grundy SM, Brewer HB, Cleeman JI, Smith SC, Lenfant D, Conference Participants, Circulation 2004 109 433 438 10.1161/01.CIR.0000111245. 75752.C6 14744958
46. Diagnosis and management of the metabolic syndrome: an American heart association/national heart, lung, and blood institute scientific statement. Grundy SM, Cleeman JI, Daniels SR, Circulation 2005 112 17 2735 2752 10.1161/CIRCULATIONAHA.105.169404 16157765
47. Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Centre for Disease Control and Prevention (CDC), MMWR 1992 41 RR-17 1 19 1480128
48. HIV viral load markers in clinical practice: recommendations of an International AIDS Society-USA Expert Panel. Saag MS, Holodniy M, Kuritzkes DR, Nat Med 1996 2 625 629 10.1038/nm0696-625 8640545
49. SPSS 16.0, Statistical package for the social sciences 16.0 Chicago, Illinois: SPSS Inc 2007
50. Lipodystrophy and dyslipidemia in human immunodeficiency virus-infected Thai patients receiving antiretroviral therapy. Chuapai Y, Kiertiburanakul S, Malathum K, Sungkanuparph S, J Med Assoc Thai 2007 90 3 452 458 17427520
51. Mechanism of highly active anti-retroviral therapy-induced hyperlipidemia in HIV-infected individuals. Carpentier A, Patterson BW, Uffelman KD, Salit I, Lewis GF, Atherosclerosis 2005 178 1 165 172 10.1016/j.atherosclerosis.2004.07. 035 15585214
52. Antiretroviral treatment reduces very-low-density lipoprotein and intermediate-density lipoprotein apolipoprotein B fractional catabolic rate in human immunodeficiency virus-infected patients with mild dyslipidemia. Shahmanesh M, Das S, Stolinski M, Shojaee-Moradie F, Jackson NC, Jefferson W, Umpleby AM, Clin Endocrinol Metab 2005 90 2 755 760
53. Alterations in liver, muscle, and adipose tissue insulin sensitivity in men with HIV infection and dyslipidemia. Reeds DN, Yarasheski KE, Fontana L, Cade WT, Laciny E, DeMoss A, Klein S, Am J Physiol Endocrinol Metab 2006 290 1 47 E53 16118251
54. HIV protease inhibitors stimulate hepatic triglyceride synthesis. Lenhard JM, Croom DK, Weiel JE, Winegar DA, Arterioscler Thromb Vasc Biol 2000 20 12 2625 2629 10.1161/01.ATV.20.12.2625 11116063
55. LDLreceptors expression in HIVinfected patients: relations to antiretroviral therapy, hormonal status, and presence of lipodystrophy. Petit JM, Duong M, Duvillard L, Florentin E, Portier H, Lizard G, Verges B, Am J Physiol EndocrinolMetab 2002 32 5 354 359
56. Adverse metabolic consequences of HIV protease inhibitor therapy: the search for a central mechanism. Hruz PW, Murata H, Mueckler M, Am J Physiol Endocrinol Metab 2001 280 4 549 E553 11254460
57. Agerelated changes in the liver sinusoidal endothelium. Couteur L, David G, Cogger VC, Mccuskey RS, De Cabo RAFAEL, Smedsrod B, Fraser R, Ann N Y Acad Sci 2007 1114 1 79 87 10.1196/annals.1396.003 17804522
58. Gender differences in Lipids and Lipoprotein (A) profiles in healthy individuals and patients with type 2 Diabetes Mellitus. Habib SS, Aslam M, Hameed W, Pak J Physiol 2005 1 1 2
59. Patient characteristics and costs associated with dyslipidaemia and related conditions in HIVinfected patients: a retrospective cohort study. Richter A, Pladevall M, Manjunath R, Lafata JE, Xi H, Simpkins J, Irish W, HIV Med 2005 6 2 79 90 10.1111/j.1468-1293.2005.00269.x 15807713
60. Associations among race/ethnicity, ApoC-III genotypes, and lipids in HIV-1-infected individuals on antiretroviral therapy. Foulkes AS, Woh DA, Frank I, Puleo E, Restine S, Megan LW, PLoS Med 2006 3 3 0337 0347
61. Racial differences in changes of metabolic parameters and body composition in antiretroviral therapy-naive persons initiating antiretroviral therapy. Gibert CL, Shlay JC, Sharma S, Bartsch G, Peng G, Grunfeld C, JAIDS 2009 50 1 44 53 10.1097/QAI.0b013e31818ce808 19295334
62. Factors associated with abdominal obesity among HIV-infected adults on antiretroviral therapy in Malaysia. Hejazi N, Lee MHS, Lin KG, Choong CLK, GJHS 2010 2 2 20
63. Alcohol drinking, the metabolic syndrome and diabetes in a population with high mean alcohol consumption. Clerc O, Nanchen D, Cornuz J, Marques-Vidal P, Gmel G, Daeppen JB, Rodondi N, Diabetic Med 2010 27 11 1241 1249 10.1111/j.1464-5491.2010.03094.x 20950381
64. Dyslipidemia and cardiovascular disease risk factor management in HIV-1-infected subjects treated with HAART in the Spanish VACH cohort. Domingo P, Suarez-Lozano I, Teir R, Lozano F, Terrón A, Viciana P, Garrido M, Open AIDS J 2008 2 26 10.2174/1874613600802010026 18923695
65. Effects of fenofibrate treatment On cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome the fenofibrate intervention and event lowering in diabetes (FIELD) study. Scott R, O'Brien R, Fulcher G, Pardy C, D'Emden M, Tse D, Keech A, Diabetes Care 2009 32 3 493 498 10.2337/dc08-1543 18984774
66. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. Perlemuter G, Sabile A, Letteron P, Vona G, Topilco A, Chrétien Y, Bréchot C, The FASEB J 2002 16 2 185 194 10.1096/fj.01-0396com
67. Metabolic and cardiovascular risk profiles and hepatitis C virus infection in rural Egypt. Marzouk D, Sass J, Bakr I, El Hosseiny M, Abdel-Hamid M, Rekacewicz C, Fontanet A, Gut 2007 56 8 1105 1110 10.1136/gut.2006.091983 16956918
68. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Shintani Y, Fujie H, Miyoshi H, Tsutsumi T, Tsukamoto K, Kimura S, Koike K, Gastroenterology 2004 126 3 840 848 10.1053/j.gastro.2003.11.056 14988838